Great headline! "... 'Significant' Revenue Increase" Their test kit rev was already in nice shape (although you wouldn't know it from the stock price), so today's news is exciting. I guess folks considered this a temporary income, so they didn't factor it into DM's value, but as sales continue to ramp up; nay-sayers can no longer deny its longevity.
Yes, it's kind of uncomfortable to get excited about money made off of this aweful virus, but DM is helping to control the spread. The new variant is super contagious, and in the words of the Pfizer ceo, it will likely mutate into a vaccine-resistant strain. To boot, it appears that the world will not lock down again for various reasons (mainly monetary?). So, is testing here to stay? It seems it will become standard practice, at least until a cure is found. Speaking of a cure:
*SPAM ALERT* Ultimately, we want to see the end of this pandemic, so If you're open to pharmaceutical risk, check out Claritas Pharmaceuticals Inc (CLAS on the TSXV), a little clinical stage biopharmaceutical company (with tons of haters like investors who've been burned by this company's past failures and dilution, and of course, the short players). But we never invest more money than we can afford to lose, right? (Yeah, right! Lol) Their current drug, now in phase one testing, is called
R-107 and is touted as a cure for pulmonary arterial hypertension (PAH) and covid. Maybe you're aware of the importance of and problems with nitric oxide in severe covid cases. Claritas's first-ever, safe, nitric oxide delivery method, currently being developed as a life-saving drug, is the
only reason that I bought shares.
"R-107 transforms Nitric Oxide into a practical therapy
What Advantages Does R-107 Have Over Nitric Oxide:
R-107 overcomes the issues with nitric oxide gas, and transforms nitric oxide therapy into a potentially best-of-care treatment for COVID-19 infection – even in a pandemic situation. Unlike nitric oxide, which must be administered as an inhalation therapy, R-107 is a liquid that is readily administered by a single intramuscular injection. Due to its ease of administration, R-107 will allow for thousands of patients to be treated simultaneously, without the need for special delivery equipment or trained respiratory therapists.
R-107 provides sustained delivery of Nitric Oxide over a 24-hour period:
Unlike nitric oxide, which has a half-life of only a few seconds after being absorbed in the lung, R-107 slowly releases nitric oxide all tissues of the body over 24-hours
R-107 delivers Nitric Oxide systemically throughout the body – not just in the lungs:
After injection, R-107 enters the bloodstream, where it begins to deliver nitric oxide systemically throughout the body, thus allowing the nitric oxide release to potentially eliminate the SARS-CoV-2 virus in all tissues, not only in the lungs.
Currently, Nitric Oxide is a gas that must be administered as an inhalation therapy like when you're in dire condition and need to be put on a ventilator. Administration of nitric oxide gas requires special CPAP-like delivery equipment and administration by a trained respiratory therapist twice per day, which substantially limits the number of patients that can be treated at any one time. As such, nitric oxide is not a practical treatment in a pandemic situation."
R-107 is the answer to Covid-19 and PAH in my humble opinion
https://claritaspharma.com/our-science/nitric-oxide-technology/